Want to see HK:1498 full AI Analyst Report?
PuraPharm Corp. Ltd. (1498) AI Stock Analysis
PuraPharm Corp. Ltd.
(HKEX:1498)
The score is primarily held back by weak financial performance—multi-year net losses, shrinking revenue, and high leverage—despite strong gross margins and recent positive free cash flow. Technicals add further pressure as the stock trades below major moving averages with negative MACD. Valuation is difficult to support due to the negative P/E and no dividend yield data.
PuraPharm Corp. Ltd. (1498) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 123.06M
- Dividend Yield
- ―
- Average Volume (3M)
- 74.53K
- Price to Earnings (P/E)
- -4.0
- Beta (1Y)
- 0.29
- Revenue Growth
- -6.71%
- EPS Growth
- 43.14%
- Country
- Hong Kong
- Employees
- 460
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
PuraPharm Corp. Ltd. Business Overview & Revenue Model
Company Description
PuraPharm Corporation Limited, an investment holding entity, focuses on the research, development, manufacturing, and global distribution of concentrated Chinese medicine granules (CCMG) and various Chinese healthcare products across Hong Kong, Mainl...
PuraPharm Corp. Ltd. Financial Statement Overview
Summary
Strong gross margins (~53% in 2023–2025) and positive operating/free cash flow in 2022–2025 support the score, but persistent EBIT and net losses (including ~-10% net margin in 2025), multi-year revenue contraction, and elevated leverage (debt-to-equity ~2.7x in 2025) materially weaken overall financial quality.
Income Statement
34NegativeBalance Sheet
28NegativeCash Flow
45Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 323.49M | 336.11M | 382.09M | 406.86M | 448.07M | 659.59M |
| Gross Profit | 176.58M | 180.16M | 205.14M | 216.63M | 260.59M | 421.85M |
| EBITDA | 38.05M | 28.30M | 36.42M | -26.31M | -46.34M | -40.03M |
| Net Income | -27.66M | -35.22M | -35.44M | -106.08M | -120.21M | -121.88M |
Balance Sheet | ||||||
| Total Assets | 699.82M | 693.76M | 715.73M | 843.96M | 1.02B | 1.21B |
| Cash, Cash Equivalents and Short-Term Investments | 12.23M | 21.18M | 12.79M | 47.22M | 91.36M | 85.05M |
| Total Debt | 370.62M | 351.14M | 363.76M | 424.77M | 503.16M | 531.96M |
| Total Liabilities | 574.86M | 560.59M | 604.53M | 690.73M | 757.18M | 803.13M |
| Stockholders Equity | 124.96M | 130.48M | 111.20M | 153.24M | 258.29M | 401.56M |
Cash Flow | ||||||
| Free Cash Flow | -26.91M | 25.69M | 89.18M | 57.95M | 42.29M | -45.89M |
| Operating Cash Flow | -25.16M | 28.52M | 103.98M | 79.61M | 65.85M | -39.33M |
| Investing Cash Flow | -4.04M | 24.12M | -11.71M | -18.20M | -25.45M | 6.00M |
| Financing Cash Flow | -802.00K | -46.34M | -86.43M | -122.39M | -12.94M | -13.87M |
PuraPharm Corp. Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1498, the sentiment is Negative. The current price of 0.23 is below the 20-day moving average (MA) of 0.24, below the 50-day MA of 0.26, and below the 200-day MA of 0.30, indicating a bearish trend. The MACD of -0.01 indicates Negative momentum. The RSI at 29.21 is Positive, neither overbought nor oversold. The STOCH value of 11.11 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1498.
PuraPharm Corp. Ltd. Peers Comparison
Overall Rating
HK:023977Outperform
HK:095068Neutral
HK:089758.6Neutral
HK:689655.5Neutral
HK:085854Neutral- HK:149843Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:0239 | 77Outperform | HKD 774.43M | 7.76 | 13.59% | 7.44% | 10.63% | 39.44% |
| HK:0950 | 68Neutral | HKD 606.50M | 3.64 | 8.02% | 5.61% | 7.05% | 22.46% |
| HK:0897 | 59Neutral | HKD 401.18M | 100.00 | 0.34% | ― | -8.30% | -44.44% |
| HK:6896 | 56Neutral | HKD 1.44B | 5.82 | 16.70% | 17.44% | -5.37% | -18.03% |
| HK:0858 | 54Neutral | HKD 147.90M | -0.13 | -154.56% | ― | -7.12% | -523.61% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:1498 | 43Neutral | HKD 123.04M | -4.04 | -21.66% | ― | -6.71% | 43.14% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:1498 | PuraPharm Corp. Ltd. | 0.23 | -0.19 | -45.24% | |
| HK:0858 | Extrawell Pharmaceutical Holdings Limited | 0.05 | -0.04 | -44.57% | |
| HK:0897 | Wai Yuen Tong Medicine Holdings Limited | 0.36 | -0.10 | -21.74% | |
| HK:0950 | Lee's Pharmaceutical Holdings Limited | 1.03 | -0.77 | -42.94% | |
| HK:0239 | Pak Fah Yeow International Limited | 2.48 | 0.25 | 11.09% | |
| HK:6896 | Golden Throat Holdings Group Co Ltd | 1.95 | -1.15 | -37.14% |
PuraPharm Corp. Ltd. Corporate Events
PuraPharm Wins Unanimous Shareholder Backing for Auditor Change
PuraPharm Corporation Limited has announced that shareholders approved, by poll, the immediate resignation of BDO Limited as its auditor at an extraordinary general meeting held on 30 October 2026. The entire voting share base was eligible to partici...
PuraPharm Calls October EGM to Approve Change of Auditor
PuraPharm Corporation Limited has called an extraordinary general meeting in Hong Kong on 30 October 2026 to seek shareholder approval for changes to its external auditor. The company will ask investors to ratify the resignation of BDO Limited and ap...
PuraPharm Moves to Replace Auditor BDO Over Fee Considerations
PuraPharm Corporation Limited has announced a proposed change of auditor, with BDO Limited resigning effective at the conclusion of the forthcoming shareholders’ general meeting after the Board moved to adjust audit arrangements due to fee cons...
PuraPharm Narrows Interim Loss Despite Revenue Decline
PuraPharm reported interim revenue of HK$159.7 million for the six months ended 30 June 2026, down 7.3% year-on-year, with gross profit slipping 3% to HK$92.3 million. The core Hong Kong and overseas CCMG segment grew modestly by 2%, while Chinese he...
PuraPharm Sets Board Meeting to Approve Interim Results and Consider Dividend
PuraPharm Corporation Limited has scheduled a board meeting for 26 August 2026 to review and approve the Group’s interim results for the six months ended 30 June 2026. The board will also decide on the publication of the interim results announc...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 10, 2026